|View printer-friendly version|
|CytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate Probody From Collaboration|
“Selecting a candidate for the CTLA-4 Probody program is a pivotal development in our partnership with
CTLA-4, a clinically validated inhibitory immune checkpoint protein, is the most advanced target from the companies’ collaboration, which now also includes three additional, unnamed targets in discovery.
“Advancing our CTLA-4 Probody program to clinical candidate stage with
About the Collaboration Agreement
Corporate Communications Contact: